Navigation Links
Arena Submits Response to FDA Complete Response Letter for Lorcaserin
Date:1/3/2012

ed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena submitted the original NDA for lorcaserin in December 2009, and the FDA issued a CRL in October 2010. Arena submitted a response to the lorcaserin CRL in December 2011, and it expects that in January 2012 the FDA will assign a new PDUFA date. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA.

Lorcaserin Phase 3 Clinical Trial Program OverviewThe lorcaserin Phase 3 clinical trial program consists of three double-blind, randomized, placebo-controlled trials, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM, and enrolled approximately 7,800 patients. BLOOM and BLOSSOM evaluated lorcaserin versus placebo in patients who are obese or patients who are overweight and have at least one weight-related co-morbid condition. BLOOM evaluated 3,182 patients over a two-year treatment period, and BLOSSOM evaluated 4,008 patients over a one-year treatment period. BLOOM-DM evaluated 604 obese and overweight patients with type 2 diabetes over a one-year treatment period. The trials included a standardized program of moderate diet and exercise guidance.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammator
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
4. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
6. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
7. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
8. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
10. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
11. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... WEST ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. ... formal affiliation agreement that allows Kessler Foundation and ... to advance biomedical research, education and patient care ... , president and chief executive officer of Kessler ... of New Jersey Health Foundation. "The ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
(Date:9/30/2014)... Ariz. , Sept. 30, 2014 Passport ... North America , has launched FluFree.com, a website ... flu vaccinations. For 20 years, Passport Health ... including the flu. The launch of FluFree.com is designed ... vaccination and the number of people who actually chose ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... 26 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Pharmaceuticals, Inc. (Huxley), which has rights to a ... the rare autoimmune disease Lambert Eaton Myasthenic Syndrome ... Products for Human Use of the European Medicines ...
... PINNACLE Network (TM) Links Thousands of Clinical ... Excellence , WASHINGTON, Oct. 26 The ... of the PINNACLE Network(TM), the first-ever registry-based cardiovascular ... each other and to the ACC,s National Cardiovascular ...
Cached Medicine Technology:BioMarin Acquires Huxley Pharmaceuticals, Inc. 2BioMarin Acquires Huxley Pharmaceuticals, Inc. 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 4BioMarin Acquires Huxley Pharmaceuticals, Inc. 5BioMarin Acquires Huxley Pharmaceuticals, Inc. 6American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 2American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 3
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
(Date:9/30/2014)... Clearwater, FL (PRWEB) September 30, 2014 ... (colon), declines with age, poor diet, and stress, so ... beneficial bacteria.* Each capsule of Ultimate Flora™ Men’s ... 58 billion cultures from 7 Bifidobacteria strains to support ... gas tends to build up, and 32 billion cultures ...
(Date:9/30/2014)... of Defense has made progress in reducing the stigma ... depression and post-traumatic stress disorder, but more improvement is ... , Despite efforts of both the Defense Department and ... many service members still do not seek needed care ... a concerted effort to promote treatment as a way ...
Breaking Medicine News(10 mins):Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3
... Jan. 3 DaVita Inc. (NYSE:,DVA) announced today that ... January 7-11, 2008 at the Westin St. Francis Hotel ... will be presenting on,January 8, at 9:00 a.m. Pacific ... presentation will also be broadcast live and by replay. ...
... ... Replace Current TIME-2 ... Trial ... KOSN ) today announced that the Tanespimycin in,Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for ...
... Continuing its role as a,leading supporter and ... of Preferred Provider Organizations (AAPPO) today,announced a ... that will significantly enhance benefits for members ... consumerism continue to fuel,further change in the ...
... live on surfaces for several days, experts say, , , THURSDAY, ... called the stomach flu, can be passed from one person ... computer keyboards and computer mice, U.S. health officials report. , ... most frequent cause of outbreaks of vomiting and diarrhea in ...
... Body Image, Cancer, and Breast-feeding Examined, ARLINGTON ... past scientific findings and developing new,knowledge about the ... Plastic and Reconstructive Surgery(R) (PRS), the official,medical journal ... sheds,new light on the psychological impact and health ...
... PARK, Ill., Jan. 3 Abbott (NYSE: ABT ... full year,ended Dec. 31, 2007, on Wednesday, Jan. 23, ... be followed by a live webcast of the earnings,conference ... and will be,accessible through Abbott,s Investor Relations Web site ...
Cached Medicine News:Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 3Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 4Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 5Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 6Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Stomach Flu Spread By Contaminated Computer Keyboards 2Health News:Stomach Flu Spread By Contaminated Computer Keyboards 3Health News:ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants 2
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Blunt tlpped forceps wlth smooth jaws that have been diamond dusted for enhanced grasping. Excellent for grasping of immature membranes....
Microforceps : Asymmetrical Endgripping Forceps...
Medicine Products: